Chemomab Therapeutics Ltd expected to post a loss of 33 cents a share - Earnings Preview

Chemomab Therapeutics

09/11/2022 11:01

* Chemomab Therapeutics Ltd  CMMB.OQ   CMMB.O  is expected
to show
no change in quarterly revenue when it reports  results on
November 11. 
    * 
    * ​Refinitiv's mean analyst estimate for Chemomab
Therapeutics Ltd
is for a loss of 33 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Chemomab
Therapeutics Ltd is $21​, above​ its last closing price
of $2.11. ​​​

This summary was machine generated November 9 at 11:00 GMT.  All
figures in US dollars  unless otherwise stated